| 1 |
Facheris G, Cossali G, Imbrescia J, et al. Real-world insights into the impact of durvalumab on stage Ⅲ unresectable non-small cell lung cancer-a narrative review[J]. Cancers (Basel), 2025，17(5): 874.
|
| 2 |
喻星豪，黄娜，刘罡. 肺癌的靶向与免疫联合治疗的研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2025, 18(2): 330-333.
|
| 3 |
Curran Jr Walter J, Paulus Rebecca, Langer Corey J, et al. Sequential vs. concurrent chemoradiation for stage Ⅲ non-smal cell lung cancer：randomized phase Ⅲ trial RTOG 9410[J]. J Natl Cancer Inst, 2011, 103(19): 1452-1460.
|
| 4 |
Oncology Society of Chinese Medical Association. [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)][J]. Zhonghua Yi Xue Za Zhi, 2025, 105(34): 2918-2959.
|
| 5 |
Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer[J]. N Engl J Med, 2017, 377(20): 1919-1929.
|
| 6 |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南2025(V1)[M]. 北京：人民卫生出版社，2025: 23-46.
|
| 7 |
Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer[J]. J Clin Oncol, 2022, 40(12): 1301-1311.
|
| 8 |
Bradley JD, Sugawara S, Lee KH, et al. Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage Ⅲ non-small cell lung cancer: the phase Ⅲ PACIFIC-2 study[J]. J Clin Oncol, 2025, 43(33): 3610-3621.
|
| 9 |
Zhou Q, Chen M, Jiang O, et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage Ⅲ non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial[J]. Lancet Oncol, 2022, 23(2): 209-219.
|
| 10 |
Wu YL, Wu L, Bi N, et al. PACIFIC-5: a phase Ⅲ clinical trial of consolidation durvalumab in patients with unresectable stage Ⅲ NSCLC and no progression after concurrent or sequential chemoradiotherapy[J]. J Hematol Oncol, 2025, 18(1): 111.
|
| 11 |
Garassino MC, Khalifa J, Reck M, et al. Durvalumab after sequential chemoradiotherapy in unresectable stage Ⅲ non-small-cell lung cancer-final analysis from the phase Ⅱ PACIFIC-6 trial[J]. ESMO Open, 2025, 10(6): 105071.
|
| 12 |
Mitsudomi T, Ito H, Okada M, et al. Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816[J]. Cancer Sci, 2024, 115(2): 540-554.
|
| 13 |
Heymach JV, Harpole D, Mitsudomi T, et al. AEGEAN Investigators. Perioperative durvalumab for resectable non-small-cell lung cancer[J]. N Engl J Med, 2023, 389(18): 1672-1684.
|
| 14 |
Johnson ML, Cho BC, Luft A, et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase Ⅲ POSEIDON study[J]. J Clin Oncol, 2023, 41(6): 1213-1227.
|
| 15 |
Filippi AR, Bar J, Chouaid C, et al. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage Ⅲ NSCLC: interim analysis of overall survival from PACIFIC-R[J]. ESMO Open, 2024, 9(6): 103464.
|
| 16 |
Wang C, Wang W, Liu H, et al. RATIONALE-315 investigators. Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial[J]. Ann Oncol, 2025: S0923-7534(25)06287-8.
|
| 17 |
Shukla NA, Althouse S, Meyer Z, et al. Association of immune-related adverse events and efficacy outcomes with consolidation pembrolizumab after chemoradiation in patients with inoperable stage Ⅲ non-small-cell lung cancer[J]. Clin Lung Cancer, 2021, 22(4): 274-281.
|
| 18 |
Jun S, Shukla NA, Durm G, et al. Analysis of circulating tumor DNA predicts outcomes of short-course consolidation immunotherapy in unresectable stage Ⅲ NSCLC[J]. J Thorac Oncol, 2024, 19(10): 1427-1437.
|
| 19 |
Herbst RS, Garon EB, Kim DW, et al. Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC[J]. J Thorac Oncol, 2021, 16(10): 1718-1732.
|
| 20 |
Borghaei H, Gettinger S, Vokes EE, et al. Five-year outcomes from the randomized, phase Ⅲ trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer[J]. J Clin Oncol, 2021, 39(7): 723-733.
|
| 21 |
Lu S, Kato T, Dong X, et al. Osimertinib after chemoradiotherapy in stage Ⅲ EGFR-mutated NSCLC[J]. N Engl J Med, 2024, 391(7): 585-597.
|
| 22 |
Meng X, Bi N, Wang J, et al. Chinese society of clinical oncology (CSCO) radiation therapy expert committee, consensus expert group. consensus on the diagnosis and treatment of unresectable stage Ⅲ driver gene-positive non-small cell lung cancer[J]. Cancer Lett, 2026, 639: 218223.
|
| 23 |
Cao H, Zhu W, Tang H, et al. Dissecting the clinicopathologic, genomic, and prognostic significance of anaplastic lymphoma kinase rearrangement in resected lung adenocarcinoma[J]. J Thorac Cardiovasc Surg, 2025, 169(4): 1143-1152.
|
| 24 |
Nassar AH, Jayakrishnan R, Feng J, et al. Consolidation ALK tyrosine kinase inhibitors versus durvalumab or observation after chemoradiation in unresectable stage Ⅲ ALK-positive NSCLC[J]. J Thorac Oncol, 2025, 20(1): 109-118.
|
| 25 |
Riely GJ, Wood DE, Aisner DL, et al. NCCN guidelines insights: non-small cell lung cancer, version 7.2025[J]. J Natl Compr Canc Netw, 2025, 23(9): 354-362.
|
| 26 |
Meng X, Bi N, Wang J, et al. Chinese society of clinical oncology (CSCO) radiation therapy expert committee, consensus expert group. consensus on the diagnosis and treatment of unresectable stage Ⅲ driver gene-positive non-small cell lung cancer[J]. Cancer Lett, 2026, 639: 218223.
|
| 27 |
Reck M, Gadgeel S, Borghaei H, et al. Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage Ⅲ non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial[J]. JAMA Oncol, 2021, 7(9): 1-9.
|
| 28 |
Peters S, Felip E, Dafni U, et al. Progression-free and overall survival for concurrent nivolumab with standard concurrent chemoradiotherapy in locally advanced stage ⅢA-B NSCLC: Results from the european thoracic oncology platform NICOLAS phase Ⅱ trial (European Thoracic Oncology Platform 6-14) [J]. J Thorac Oncol, 2021, 16(2): 278-288.
|
| 29 |
Jabbour SK, Cho BC, Bria E, et al. Rationale and design of the phase Ⅲ KEYLYNK-012 study of pembrolizumab and concurrent chemoradiotherapy followed by pembrolizumab with or without olaparib for stage Ⅲ non-small-cell lung cancer[J]. Clin Lung Cancer, 2022, 23(6): e342-e346.
|
| 30 |
De Ruysscher D, Ramalingam S, Urbanic J, et al. CheckMate 73L: A phase 3 study comparing nivolumab plus concurrent chemoradiotherapy followed by nivolumab with or without ipilimumab versus concurrent chemoradiotherapy followed by durvalumab for previously untreated, locally advanced stage Ⅲ non-small-cell lung cancer[J]. Clin Lung Cancer, 2022, 23(3): e264-e268.
|
| 31 |
Deng J, Zhu Z. Advances in the research on radiotherapy for lung cancer: a 2025 review[J]. Transl Lung Cancer Res, 2026, 15(3): 64.
|
| 32 |
Acker F, Reck M, Martin D, et al. Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage Ⅲ unresectable non-small cell lung cancer: A systematic review and meta-analysis[J]. Eur J Cancer, 2025, 218: 115266.
|
| 33 |
中国医师协会肿瘤多学科诊疗专业委员会，国家肿瘤质控中心肺癌质控专家委员会．肺癌免疫检查点抑制剂联合放疗中国专家共识(2025版)[J]. 中华肿瘤杂志，2025, 47(1): 39-64.
|
| 34 |
中国抗癌协会肿瘤多学科诊疗(MDT)专业委员会，中国抗癌协会肿瘤放射治疗专业委员会，中国抗癌协会肺癌专业委员会，等. 不可切除肺癌放疗联合免疫治疗中国专家共识(2026年版)[J]. 中华肿瘤防治杂志，2026, 33(3): 133159.
|
| 35 |
Seymour L, Bogaerts J, Perrone A, et al. RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics[J]. Lancet Oncol, 2017, 18(3): e143-e152.
|